Potential renoprotective effects of piceatannol in ameliorating the early-stage nephropathy associated with obesity in obese Zucker rats

• Marta Llarena ^[4] ; Fernando Andrade ^[4] ; Mounia Hasnaoui ^[5] ; María P. Portillo ^[1] ; Patricia Pérez-Matute ^[2] ; Jose M. Arbones-Mainar ^[3] ; Elizabeth Hijona ^[1] ; María Jesús Villanueva-Millán ^[2] ; Leixuri Aguirre ^[1] ; Christian Carpéné ^[5] ; Luis Aldámiz-Echevarría ^[4]
  1. [1] Universidad del País Vasco/Euskal Herriko Unibertsitatea

     Universidad del País Vasco/Euskal Herriko Unibertsitatea

     Leioa, España

     
  2. [2] Centro de Investigación Biomédica de La Rioja

     Centro de Investigación Biomédica de La Rioja

     Logroño, España

     
  3. [3] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  4. [4] Cruces University Hospital
  5. [5] Institut des Maladies Métaboliques et CardiovasculairesInstitut National de la Santé et de la Recherche Médicale (INSERM U1048)

  Mostrar afiliaciones +
• Localización: Journal of physiology and biochemistry, ISSN-e 1877-8755, ISSN 1138-7548, Vol. 72, Nº. 3, 2016, págs. 555-566
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Obesity-associated nephropathy is considered to be a leading cause of end-stage renal disease. Resveratrol supplementation represents a promising therapy to attenuate kidney injury, but the poor solubility and limited bioavailability of this polyphenol limits its use in dietary intervention. Piceatannol, a resveratrol analogue, has been suggested as a better option. In this study, we aimed to provide evidence of a preventive action of piceatannol in very early stages of obesity-associated nephropathy. Thirty obese Zucker rats were divided into three experimental groups: one control and two groups orally treated for 6 weeks with 15 and 45 mg piceatannol/kg body weight/day. Enzyme-linked immunosorbent assays (ELISA) were used to determine renal and urinary kidney injury molecule-1 (Kim-1), renal fibrosis markers (transforming growth factor β1 and fibronectin) and renal sirtuin-1 protein. Oxidative stress was assessed in the kidney by measuring lipid peroxidation and nitrosative stress (thiobarbituric acid reactive substrates and 3-nitrotyrosine levels, respectively) together with the activity of the antioxidant enzyme superoxide dismutase. Renal fatty acids profile analysis was performed by thin-layer and gas chromatography. Piceatannol-treated rats displayed lower levels of urinary and renal Kim-1. Renal fibrosis biomarkers and lipid peroxidation exhibited a tendency to decrease in the piceatannol-treated groups. Piceatannol treatment did not modify superoxide dismutase activity or sirtuin-1 protein levels, while it seemed to increase the levels of polyunsaturated and omega-6 polyunsaturated fatty acids in the kidneys. Our findings suggest a mild renoprotective effect of piceatannol in obese Zucker rats and the need of intervention at early stages of renal damage.